OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:31 UTC. Every row links to its source record.

CCND2 cyclin D2

ENSG00000118971 · protein coding · Open Targets profile

Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed:18827403, PubMed:8114739). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase (PubMed:18827403, PubMed:8114739). Hypophosphorylates RB1 in early G(1) phase (PubMed:18827403, PubMed:8114739). Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals (PubMed:18827403, PubMed:8114739). {ECO:0000269|PubMed:18827403, ECO:0000269|PubMed:8114739}.

In 8 of 15 cancers, the evidence for CCND2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751colorectal cancercolorectal cancercolorectal cancer: germline 0.79colonic neoplasmcolonic neoplasmcolonic neoplasm: germline 0.69B-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemia: somatic 0.52colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.46colorectal adenocarcinoma: germline 0.55benign colon neoplasmbenign colon neoplasmbenign colon neoplasm: germline 0.64colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.46colon adenocarcinoma: germline 0.51superficial spreading melanomasuperficial spreading melanomasuperficial spreading melanoma: somatic 0.61nodular malignant melanomanodular malignant melanomanodular malignant melanoma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61anus neoplasmanus neoplasmanus neoplasm: germline 0.59rectal neoplasmrectal neoplasmrectal neoplasm: germline 0.59

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Ligand, Druggable Family
PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.1984899938106537 (upper bound 0.391759991645813). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of CCND2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of CCND2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.